Petros Pharmaceuticals Inc

NASDAQCM:PTPI

Estados Unidos / Salud / Productos farmacéuticos

Visión general

Dividendos

Finanzas históricas a 5 años

Precio

0.09 USD


Key Metrics	Latest
Total Revenue	4.022 M
Adjusted EBITDA	-10.61 M
EBITDA Margin	-263.8%
Net Profit Margin	-165.2%
Total Assets	20.694 M
Total Debt	7.34 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	12 Months	Sep-23	Sep-24

Revenue	15.58	9.56	7.81	5.99	5.82	4.02	6.19	4.39
% Growth		(0.39)	(0.18)	(0.23)	(0.03)			(0.29)

Adjusted EBITDA	(11.58)	(10.62)	(11.17)	(10.25)	(7.48)	(10.61)	(3.24)	(6.37)
% Margin	(0.74)	(1.11)	(1.43)	(1.71)	(1.28)	(2.64)	(0.52)	(1.45)

Adjusted EBIT	(16.87)	(17.28)	(18.05)	(15.85)	(10.76)	(13.59)	(5.72)	(8.55)
% Margin	(1.08)	(1.81)	(2.31)	(2.64)	(1.85)	(3.38)	(0.93)	(1.95)

Adjusted Net Income	(30.70)	(20.59)	(15.96)	(17.37)	(10.08)	(6.64)	(8.48)	(5.05)
% Margin	(1.97)	(2.15)	(2.04)	(2.90)	(1.73)	(1.65)	(1.37)	(1.15)

Adjusted Basic EPS	(124.81)	(38.55)	(14.66)	(8.39)	(4.63)	(0.90)	(4.02)	(0.69)

Cálculos de apoyo

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Sep-24	Sep-23	Sep-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	16	10	8	6	6	4	6	4
% Growth	NA	-38.6%	-18.3%	-23.3%	-2.8%			-29.1%

Cost of Revenue	(7)	(4)	(2)	(2)	(2)	(1)	(1)	(1)
Gross Profit	8	6	6	4	4	3	5	3
% Revenue	52.3%	57.7%	79.5%	61.8%	72.0%	72.5%	76.2%	78.4%

Research and Development	0	(0)	(2)	(2)	(2)	(3)	(2)	(3)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(20)	(16)	(16)	(12)	(9)	(10)	(6)	(7)
Other Inc / (Exp)	(8)	(8)	3	(9)	(1)	6	(5)	1
Total Operating Exp	(27)	(24)	(15)	(23)	(12)	(8)	(13)	(8)

Operating Income	(19)	(19)	(9)	(19)	(8)	(5)	(8)	(5)
% Revenue	-124.0%	-198.4%	-110.3%	-324.7%	-139.8%	-118.9%	-135.1%	-114.0%

Interest Expense	(14)	(3)	(0)	(1)	(0)	0	(0)	(0)
Pre-tax Income	(33)	(22)	(9)	(20)	(8)	(5)	(8)	(5)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	1	1	0	0	0	0	0	0
Net Income to Company	(33)	(21)	(9)	(20)	(8)	(5)	(8)	(5)
% Margin	-208.7%	-215.3%	-115.0%	-334.4%	-140.2%	-117.5%	-137.1%	-115.0%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	(33)	(21)	(9)	(20)	(8)	(5)	(8)	(5)

Preferred Dividends	0	0	0	0	1	2	0	2
Other Adj.	0	0	0	0	(6)	(17)	(2)	(13)

Net Income to Common	(33)	(21)	(9)	(20)	(14)	(20)	(10)	(16)
% Margin	-208.7%	-215.3%	-115.0%	-334.4%	-237.3%	-493.5%	-161.2%	-364.9%

As Reported
Basic EPS (Continuing Ops)	(132.16)	(38.55)	(8.25)	(9.68)	(6.35)	(3.80)	(4.73)	(2.18)
Diluted EPS (Continuing Ops)	(132.16)	(38.55)	(8.25)	(9.68)	(6.35)	(3.80)	(4.73)	(2.18)

WA Basic Shares Out.	0.25	0.53	1.09	2.07	2.18	7.40	2.11	7.33
WA Diluted Shares Out.	0.25	0.53	1.09	2.07	2.18	7.40	2.11	7.33

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(33)	(22)	(9)	(20)	(8)	(5)	(8)	(5)
Addback: Net Interest Expense	14	3	0	1	0	(0)	0	0
Addback: Other Non Operating Expenses, Total	0	2	0	0	(0)	(6)	3	(4)
Addback: Depreciation & Amortization	5	7	7	6	3	3	2	2
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	2	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	7	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	(9)	(4)	(3)	(3)	0	0
Adjusted EBITDA	(12)	(11)	(11)	(10)	(7)	(11)	(3)	(6)
% Margin	-74.3%	-111.1%	-143.0%	-171.0%	-128.5%	-263.8%	-52.4%	-145.3%

Adjusted EBIT	(17)	(17)	(18)	(16)	(11)	(14)	(6)	(9)
% Margin	-108.3%	-180.8%	-231.1%	-264.4%	-184.8%	-337.8%	-92.5%	-194.9%

Adjusted Net Income Reconciliation
Net Income to Company	(33)	(21)	(9)	(20)	(8)	(5)	(8)	(5)
Addback: Unusual Items	2	0	(9)	4	(3)	(3)	0	0
Less: Tax Benefit of Unusual Items (26%)	(1)	0	2	(1)	1	1	0	0
Adjusted Net Income	(31)	(21)	(16)	(17)	(10)	(7)	(8)	(5)
% Margin	-197.1%	-215.3%	-204.4%	-289.8%	-173.1%	-165.2%	-137.1%	-115.0%

Error de carga

Petros Pharmaceuticals Inc

NASDAQCM:PTPI

Estados Unidos / Salud / Productos farmacéuticos

Finanzas históricas a 5 años